Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEACS. by Bueno, H et al.
Bueno, H; Pocock, S; Medina, J; Danchin, N; Annemans, L; Licour,
M; Gregson, J; Vega, AM; van de Werf, F (2017) Association Between
Clinical Pathways Leading to Medical Management and Prognosis in
Patients With NSTEACS. Rev Esp Cardiol (Engl Ed). ISSN 1885-
5857 DOI: 10.1016/j.rec.2016.12.031
Downloaded from: http://researchonline.lshtm.ac.uk/3682743/
DOI: 10.1016/j.rec.2016.12.031
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Original article
Association Between Clinical Pathways Leading to Medical
Management and Prognosis in Patients With NSTEACS
He´ctor Bueno,a,b,c,* Stuart Pocock,d Jesu´s Medina,e Nicolas Danchin,f Lieven Annemans,g
Muriel Licour,h John Gregson,d Ana Marı´a Vega,e and Frans van de Werfi
aGrupo de Investigacio´n Multidisciplinar Traslacional, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
b Servicio de Cardiologı´a, Instituto de Investigacio´n i+12, Hospital Universitario 12 de Octubre, Madrid, Spain
c Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
dDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
eDepartamento Me´dico Global, Evidencia Me´dica e Investigacio´n Observacional, AstraZeneca, Madrid, Spain
fDepartment of Cardiology, Hoˆpital Europe´en Georges Pompidou & Rene´ Descartes University, Paris, France
gDepartment of Public Health, Universiteit Gent, Vakgroep Maatschappelijke Gezondheidkunde, Gent, Belgium
hDe´partement Me´dical, AstraZeneca France, Rueil-Malmaison, France
iDepartement Cardiovasculaire Wetenschappen, Universiteit van Leuven, Leuven, Belgium
Rev Esp Cardiol. 2017;xx(x):xxx–xxx
Article history:
Received 10 June 2016
Accepted 30 November 2016
Keywords:
Acute coronary syndrome
Medical management
Coronary revascularization
Coronary angiography
Prognosis
A B S T R A C T
Introduction and objectives: A large proportion of patients with non—ST-segment elevation
acute coronary syndrome (NSTEACS) are initially selected for medical management (MM) and do not
undergo coronary revascularization during or immediately after the index event. The aim of this study was
to explore the clinical pathways leading to MM in NSTEACS patients and their inﬂuence on prognosis.
Methods: Patient characteristics, pathways leading to MM, and 2-year outcomes were recorded in a
prospective cohort of 5591 NSTEACS patients enrolled in 555 hospitals in 20 countries across Europe and
Latin America. Cox models were used to assess the impact of hospital management on postdischarge
mortality.
Results: Medical management was the selected strategy in 2306 (41.2%) patients, of whom 669 (29%)
had signiﬁcant coronary artery disease (CAD), 451 (19.6%) had nonsigniﬁcant disease, and 1186 (51.4%)
did not undergo coronary angiography. Medically managed patients were older and had higher risk
features than revascularized patients. Two-year mortality was higher in medically managed patients
than in revascularized patients (11.0% vs 4.4%; P < .001), with higher mortality rates in patients who did
not undergo angiography (14.6%) and in those with signiﬁcant CAD (9.3%). Risk-adjusted mortality
was highest for patients who did not undergo angiography (HR = 1.81; 95%CI, 1.23-2.65), or were
not revascularized in the presence of signiﬁcant CAD (HR = 1.90; 95%CI, 1.23-2.95) compared with
revascularized patients.
Conclusions: Medically managed NSTEACS patients represent a heterogeneous population with distinct
risk proﬁles and outcomes. These differences should be considered when designing future studies in this
population.
C 2016 Sociedad Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a, S.L.U. All rights reserved.
Relacio´n entre las situaciones clı´nicas que llevan al tratamiento exclusivamente
farmacolo´gico del SCASEST y su prono´stico
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R E S U M E N
Introduccio´n y objetivos: Una proporcio´n importante de pacientes con sı´ndrome coronario agudo sin
elevacio´n del segmento ST (SCASEST) se tratan exclusivamente con fa´rmacos (TEF) sin revascularizacio´n
coronaria inicial. El objetivo del estudio es evaluar las situaciones clı´nicas que conducen al TEF y su
inﬂuencia en el prono´stico del SCASEST.
Me´todos: Se registraron las caracterı´sticas basales, las situaciones clı´nicas que llevaron a TEF y los
resultados a 2 an˜os de una cohorte prospectiva de 5.591 pacientes con SCASEST reclutados en
555 hospitales de 20 paı´ses de Europa y Ame´rica Latina. El impacto del TEF en la mortalidad tras el alta se
evaluo´ mediante modelos de surpervivencia de Cox.
* Corresponding author: Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro 3, 28029 Madrid, Spain.
E-mail address: hector.bueno@cnic.es (H. Bueno).
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INTRODUCTION
An invasive management strategy is recommended for most
patients with non—ST-segment elevation acute coronary
syndrome (NSTEACS).1–3 Nevertheless, a large proportion of
NSTEACS patients are initially managed medically; that is, they
do not undergo coronary revascularization (CR) during or
immediately after the index admission.4–6 This observation has
triggered studies designed to evaluate speciﬁc therapeutic
approaches for these patients.7–13 However, patients with
NSTEACS may be selected for medical management (MM) for a
number of different reasons, and we hypothesized that patient
proﬁles and outcomes may vary accordingly.
The aims of this analysis were to study rates of the use of the
different management strategies for NSTEACS in real-world
practice from an international perspective, the main clinical
pathways that lead to the nonuse of CR, and the relationship
between these pathways and postdischarge outcomes.
METHODS
Study Design
EPICOR (long-tErm follow-up of antithrombotic management
Patterns In acute CORonary syndrome patients - NCT01171404) is
a prospective, international, observational, real-life practice,
cohort study. The rationale, design, deﬁnitions, site selection,
and baseline patient characteristics have been published previ-
ously.14–16 Brieﬂy, 10 568 patients hospitalized for an acute
coronary syndrome, with or without ST-segment elevation, within
24 hours of symptom onset and who survived until hospital
discharge were enrolled in 555 hospitals in 20 countries in
Northern, Southern, and Eastern Europe and Latin America
between September 2010 and March 2011. Patients were excluded
from the study if they had ‘secondary’ acute coronary syndrome,
any condition or circumstance that might limit completion of
follow-up, serious comorbidities considered likely to limit life
expectancy to less than 6 months, and previous enrolment in
EPICOR or another clinical trial. All patients gave informed consent.
Medical treatments for acute coronary syndrome, diagnostic and
therapeutic procedures, and clinical events during the acute phase
(pre- and in-hospital) were recorded using electronic case report
forms. Patients were followed up by telephone calls for up to
2 years after hospital discharge. Vital status, hospitalizations,
cardiovascular and bleeding events, and changes in medication
were recorded for each call.
The deﬁnitions used in EPICOR have been presented else-
where.14,16 A diagnosis of non—ST-segment elevation myocardial
infarction required the presence of chest pain/discomfort, lack of
persistent ST-segment elevation, left bundle branch block or
intraventricular conduction disturbances, and elevation of cardiac
biomarkers (creatinine kinase-isoenzyme MB and troponins) with
at least 1 value above the 99th percentile of the upper reference
limit. Unstable angina was deﬁned as the presence of angina
symptoms at rest or on minimal exercise, and transient ST-T
changes, and no signiﬁcant increase in biomarkers of necrosis but
objective evidence of ischemia by noninvasive imaging or
signiﬁcant coronary stenosis on angiography. Cardiovascular
events included myocardial infarction, heart failure, arrhythmia,
unstable angina, ischemic stroke, and transient ischemic attack.
Bleeding events included all kinds of bleeds.
Management Strategies
Two management strategies were deﬁned for patients with
NSTEACS: a) CR, which included patients who underwent any kind
of CR (either percutaneous or surgical) during the index admission,
and b) MM, for those discharged without CR. According to the
reasons for MM, 3 subgroups were predeﬁned: a) patients who did
not undergo diagnostic coronary angiography (CAG–); b) patients
who underwent CAG and had signiﬁcant (at least 1 stenosis > 50%
in 1 coronary artery) coronary artery disease (CAD) but did not
undergo CR (CAG+, CAD+), and c) patients who underwent
angiography and had no signiﬁcant CAD (CAG+, CAD–).17
Statistical Analysis
Baseline characteristics, hospital management, and in-hospital
outcomes for patients with NSTEACS were compared according to
the initial management strategy. Comparisons were made
between CR and MM or across the 3 MM subgroups using chi-
square tests. In a second step, we investigated the independent
predictors of selection for angiography or MM. We used univariate
logistic regression models to assess any association between
angiography or MM and individual covariates. To identify the
strongest independent predictors, we used multivariable logistic
Resultados: Se utilizo´ un TEF a 2.306 pacientes (41,2%), de los que 669 (29%) tenı´an enfermedad
coronaria (EC) signiﬁcativa y 451 (19,6%), EC no signiﬁcativa y a 1.186 (51,4%) ni siquiera se les pratico´
una coronariografı´a. Los pacientes con TEF eran mayores y de ma´s riesgo. La mortalidad a 2 an˜os fue
mayor con TEF que con revascularizacio´n coronaria (el 11,0 frente al 4,4%; p < 0,001), superior para
quienes no se sometieron a coronariografı´a (14,6%) y aquellos con EC signiﬁcativa (9,3%). La mortalidad
ajustada por riesgo fue superior entre los pacientes a los que no se hizo coronariografı´a (HR = 1,81; IC95%,
1,23-2,65) o no se revascularizo´ pese a tener EC signiﬁcativa (HR = 1,90; IC95%, 1,23-2,95) que con
revascularizacio´n coronaria.
Conclusiones: Los pacientes con SCASEST en TEF constituyen una poblacio´n heteroge´nea con perﬁles de
riesgo y prono´stico diferentes. Se debe considerar estas diferencias al disen˜ar futuros estudios en esta
poblacio´n.
C 2016 Sociedad Espan˜ola de Cardiologı´a. Publicado por Elsevier Espan˜a, S.L.U. Todos los derechos reservados.
Abbreviations
CAD: coronary artery disease
CAG: coronary angiography
CR: coronary revascularization
EPICOR: long-tErm follow-up of antithrombotic
management Patterns In acute CORonary
syndrome patients
MM: medical management
NSTEACS: non—ST-segment elevation acute coronary
syndrome
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regression. We forced the inclusion of geographical region
(Northern Europe, Eastern Europe, Southern Europe, and Latin
America) and type of hospital (regional, nonuniversity general,
university general, and private) into the model. Additionally, we
ﬁtted a random-effect at the hospital level to account for within-
hospital clustering of events. We used a forward stepwise variable
selection with a P-value cut-off of .05 to select a ﬁnal model.
Finally, the impact of MM on 2-year outcomes was studied.
Comparisons of clinical outcome rates (mortality, cardiovascular
events, and bleeding events) during follow-up between the
management groups were done by ﬁtting a Cox proportional
hazards model for time to death or time to ﬁrst event, censored at
2 years postdischarge. In our minimally adjusted Cox models, we
adjusted for age, sex, geographical region, type of hospital (as
described above), and a random-effect (shared frailty) term at the
hospital level. In our fully adjusted models, we additionally
adjusted risk factors associated with 1-year mortality identiﬁed
from our previous publication.18
RESULTS
Management Strategies for Patients With Non—ST-segment
Elevation Acute Coronary Syndrome
A total of 5625 NSTEACS patients were enrolled at hospital
discharge. Data on in-hospital management strategies were
available for all except 34 (0.7%) of these. Of the remaining
5591 patients, 4405 (78.8%) underwent CAG (Figure 1). Of these,
3954 patients (70.7%) had CAD, and 3285 (58.8%) underwent CR in
hospital. Therefore, a total of 2306 patients (41.2%) were medically
managed. Most MM patients (51.4%, n = 1186) did not undergo
CAG during hospitalization (21.2% of total population), 451 (19.6%
of MM, 8.1% of total population) lacked signiﬁcant CAD, and 669
(29.0% of MM, 12.0% of total population) had signiﬁcant CAD, but
CR was not attempted (Figure 1).
Patients who received MM were older and less likely to present
with non—ST-segment elevation myocardial infarction, but more
often had prior cardiovascular disease, comorbidities, and cardio-
vascular medications (Table 1). They also had more severe cardiac
disease (Table 1). When characteristics were compared across the
3 predeﬁned subgroups of MM patients, signiﬁcant differences
were found again, with a gradient from younger age and lower
comorbidity and cardiovascular burden among CAG+ CAD–
patients to older and sicker patients among CAG– patients.
Signiﬁcant regional differences were found in the rate of MM
(data not shown).
The most important independent predictor of undergoing CAG
during the index hospitalization (Table 1 of the Supplementary
Material) was the presence of a catheterization laboratory in the
hospital (odds ratio [OR], 46.8; 95% conﬁdence interval [95%CI],
22.4-97.6). Non—ST-elevation acute myocardial infarction (OR =
1.72; 95%CI, 1.24-2.38) was associated with a higher probability of
undergoing CAG compared with unstable angina as well as prior
myocardial infarction (OR = 1.58; 95%CI, 1.07-2.32), while age >
75 years (OR = 0.38; 95%CI, 0.28-0.53), current smoking (OR = 0.67;
95%CI, 0.51-0.88), hemoglobin levels < 13 g/dL (OR = 0.65; 95%CI,
0.48-0.78), prior myocardial infarction (OR = 0.56; 95%CI, 0.39-
0.67), prior coronary artery bypass graft surgery (OR = 0.60; 95%CI,
0.38-0.94), prior heart failure (OR = 0.30; 95%CI, 0.19-0.49), and
being on angiotensin-converting enzyme inhibitors at admission
(OR = 0.70; 95%CI, 0.53-0.92) were associated with lower
probabilities. Patients from Latin America (OR = 0.04; 95%CI,
0.02-0.11) and Eastern Europe (OR = 0.15; 95%CI, 0.06-0.35) had a
lower probability of undergoing CAG than patients from Northern
Europe.
Independent predictors of not undergoing CR (Table 2 of the
Supplementary Material) among patients who underwent CAG and
had signiﬁcant CAD were prior cardiovascular disease (OR = 0.53;
95%CI, 0.42-0.67), prior coronary artery bypass graft (OR = 0.45;
95%CI, 0.32-0.63), age > 5 years (OR = 0.73; 95%CI, 0.55-0.98), and
serum creatinine > 1.2 mg/dL (OR = 0.76; 95%CI, 0.58-0.99) were
marginally associated with lower probabilities while male patients
had a higher probability (OR = 1.34; 95%CI, 1.04-1.72). Patients
from Latin America (OR = 0.29; 95%CI, 0.18-0.48) and Eastern
Europe (OR = 0.50; 95%CI, 0.33-0.87) had a lower probability of
undergoing revascularization after CAG than patients from
Northern Europe. Admission to private hospitals was associated
with an increased probability of being revascularized during
hospitalization (OR = 2.19; 95%CI, 1.14-4.20).
In-hospital Diagnostic and Therapeutic Procedures,
and Medical Treatments by Management Strategy
In general, MM patients less frequently received diagnostic and
therapeutic procedures during hospitalization than did CR patients
(Table 2). Although all antithrombotic drugs and most cardiovas-
cular preventative treatments were prescribed in most patients,
MM patients were less likely to receive them in hospital. Among
those who underwent CAG, multivessel disease was signiﬁcantly
more frequent in CR than in MM patients as a whole but not in the
subgroup of MM patients with signiﬁcant CAD. Interestingly, the
results of CAG triggered small changes in antiplatelet drugs both in
CR and MM patients, with the exception of clopidogrel, which was
withdrawn in a substantial proportion of MM patients at discharge
(Table 2).
Outcomes by Management Strategy
Patients who underwent MM had a higher incidence of in-
hospital cardiovascular complications, mainly heart failure and
atrial ﬁbrillation, particularly among those who did not undergo
CAG (Table 3). The 2-year postdischarge all-cause mortality rate
NSTEACS
5591 (100%)
CAG
4405 (78.8%)
Significant CAD
3954 (70.7%)
Revascularized
(PCI/CABG) 3285 (58.8%)
Medically managed
2306 (41.2%)
Not revascularized
669 (12.0%)
No significant CAD
451 (8.1%)
No CAG
1186 (21.2%)
Figure 1. Distribution of EPICOR NSTEACS patients according to initial
revascularization strategy and clinical pathways leading to medical
management. CABG, coronary artery bypass graft; CAD, coronary artery
disease; CAG, coronary angiography; NSTEACS, non—ST-segment elevation
acute coronary syndrome; PCI, percutaneous coronary intervention.
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was 7.0% in the whole cohort, with signiﬁcant differences between
CR and MM patients (4.4% vs 11%; P < .001) (Table 3, Figure 2A).
A gradient in 2-year mortality was also found among MM patients,
with patients who did not receive CAG showing the highest
mortality (14.6%) and those without signiﬁcant obstructive CAD
the lowest (4.1%). Cardiovascular event rates at 2 years, including
myocardial infarction, heart failure, arrhythmia, unstable angina,
ischemic stroke, and transient ischemic attack, were also
signiﬁcantly higher in MM than in CR patients (15.4% vs 9.6%;
P < .001), and were highest in those who did not receive CAG
(17.4%) (Figure 2B). In contrast, bleeding events were numerically
but not signiﬁcantly lower in MM vs CR patients (3.4% vs 4.6%;
P = .06) (Figure 2C). Among the MM subgroups, the difference
in bleeding event rates was not signiﬁcant but appeared lowest in
those who underwent CAG and had no signiﬁcant CAD. Using 70%
stenosis as the cut-off point for CAD+ did not signiﬁcantly change
the results (data not shown). Compared with the results for the 50%
cut-off point, there was a slight increase in the mortality rate in
both the CAG+CAD+ and CAG+CAD– groups, as they were both
composed of higher risk patients, with a small change in mortality
gradient between the groups. On exclusion of the 190 patients who
underwent revascularization after discharge (including 32 within
the ﬁrst month) from the analyses, no relevant differences were
found in patterns of mortality or other event rates.
Lack of CAG was found to be an independent predictor of
2-year mortality, adjusted for age, sex, and postdischarge
mortality predictors, as previously described in the EPICOR
cohort18 (hazard ratio [HR] = 1.81; 95%CI, 1.23-2.65; P < .001).
Among patients who underwent CAG, MM patients with
signiﬁcant CAD had an increased adjusted mortality risk
(HR = 1.90; 95%CI, 1.23-2.95; P < .001), while those without
signiﬁcant CAD did not (HR = 0.68; 95%CI, 0.21-2.21; P < .001)
(Table 4). Other predictors of 2-year mortality are shown in
Table 3 of the Supplementary Material.
Table 1
Baseline Characteristics of Non—ST-segment Elevation Acute Coronary Syndrome Patients by Management Strategy
CR
n = 3285 (58.8%)
MM
n = 2306 (41.2%)
P (CR vs MM) MM P
CAG–
n = 1186
(21.2%)
CAG+ CAD+
n = 669
(12.0%)
CAG+ CAD–
n = 451
(8.1%)
Diagnosis
NSTEMI (n = 5591) 2491 (75.8%) 1482 (64.3%) < .0001 725 (61.1%) 454 (67.9%) 303 (67.2%) .0051
Unstable angina (n = 5591) 794 (24.2%) 824 (35.7%) < .0001 461 (38.9%) 215 (32.1%) 148 (32.8%) .0051
Basic characteristics
Age > 75 y (n = 5591) 559 (17.0%) 553 (24.0%) < .0001 346 (29.2%) 139 (20.8%) 68 (15.1%) < .0001
Male sex (n = 5591) 2513 (76.5%) 1463 (63.4%) < .0001 750 (63.2%) 484 (72.3%) 229 (50.8%) < .0001
CV risk factors
Hypertension (n = 5525) 2084 (64.3%) 1603 (70.2%) < .0001 874 (74.3%) 466 (70.4%) 263 (59.1%) < .0001
Hypercholesterolemia (n = 5373) 1716 (54.2%) 1228 (55.6%) .311 617 (55.0%) 399 (61.8%) 212 (48.1%) < .0001
Diabetes mellitus (n = 5526) 800 (24.7%) 705 (30.9%) < .0001 412 (35.2%) 213 (32.1%) 80 (17.9%) < .0001
Current smoking (n = 5198) 996 (32.5%) 851 (39.9%) < .0001 451 (41.2%) 221 (35.6%) 179 (43.0%) .0263
Glucose > 160 mg/dL (n = 4856) 548 (19.4%) 475 (23.4%) .0007 294 (26.8%) 136 (23.4%) 45 (12.7%) < .0001
Hemoglobin < 13 mg/dL (n = 5217) 656 (21.4%) 668 (31.1%) < .0001 401 (35.5%) 174 (28.3%) 93 (23.0%) < .0001
Previous CVD
Prior CVD (n = 5547) 1372 (42.1%) 1288 (56.3%) < .0001 695 (58.8%) 399 (60.4%) 194 (43.4%) < .0001
Prior MI (n = 5510) 730 (22.5%) 728 (32.1%) < .0001 428 (36.5%) 213 (32.6%) 87 (19.6%) < .0001
Prior PCI (n = 5511) 710 (21.9%) 452 (19.9%) .081 195 (16.7%) 165 (25.2%) 92 (20.7%) < .0001
Prior CABG (n = 5544) 267 (8.2%) 264 (11.5%) < .0001 130 (11.0%) 120 (18.2%) 14 (3.1%) < .0001
Heart failure (n = 5514) 158 (4.9%) 259 (11.4%) < .0001 188 (16.1%) 46 (7.0%) 2 (5.6%) < .0001
Arial ﬁbrillation (n = 5531) 158 (4.9%) 210 (9.2%) < .0001 117 (10.0%) 54 (8.2%) 39 (8.8%) .4139
TIA/stroke (n = 5535) 197 (6.1%) 168 (7.4%) .0548 98 (8.3%) 48 (7.3%) 22 (4.9%) .0634
PVD (n = 5474) 212 (6.6%) 171 (7.6%) .1396 92 (8.0%) 62 (9.5%) 17 (3.8%) .0018
Chronic kidney disease (n = 5591) 151 (4.6%) 162 (7.0%) .0003 110 (9.3%) 42 (6.3%) 10 (2.2%) < .0001
Serum creatinine > 1.2 mg/dL (n = 5291) 680 (21.9%) 636 (29.0%) < .0001 361 (31.7%) 189 (29.9%) 86 (20.6%) < .0001
Chronic CV medication
Antiplatelets (n = 5591) 1425 (43.4%) 1179 (51.1%) < .0001 606 (51.1%) 387 (57.8%) 186 (41.2%) < .0001
Aspirin (n = 5590) 1347 (41.0%) 1108 (48.1%) < .0001 571 (48.2%) 365 (54.6%) 172 (38.1%) < .0001
Clopidogrel (n = 5585) 435 (13.3%) 397 (17.2%) < .0001 211 (17.8%) 112 (16.8%) 74 (16.4%) .7445
Anticoagulants (n = 5591) 122 (3.7%) 145 (6.3%) < .0001 84 (7.1%) 34 (5.1%) 27 (6.0%) .2241
ACE inhibitors/ARBs (n = 5577) 1358 (41.5%) 1148 (49.9%) < .0001 645 (54.5%) 316 (47.4%) 187 (41.6%) < .0001
Beta-blockers (n = 5582) 1208 (36.9%) 995 (43.2%) < .0001 533 (45.0%) 303 (45.3%) 159 (35.3%) .0008
Statins (n = 5573) 1272 (38.8%) 948 (41.3%) .0634 473 (40.2%) 301 (45.0%) 174 (38.8%) .0606
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAG, coronary angiography; CR,
coronary revascularization; CVD, cardiovascular disease; MI, myocardial infarction; MM, medical management; NSTEMI, non—ST-segment elevation myocardial infarction;
PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; TIA, transient ischemic attack.
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Table 2
Hospital Procedures and Hospital and Discharge Treatments by Management Strategy
CR
n = 3285 (58.8%)
MM
n = 2306 (41.2%)
P (CR vs MM) MM P
CAG– n = 1186
(21.2%)
CAG+ CAD+ n = 669
(12.0%)
CAG+ CAD–
n = 451 (8.1%)
Antithrombotic medications
Aspirin
Initial (n = 5591) 3122 (95.0%) 2067 (89.6%) < .0001 1033 (87.1%) 629 (94.0%) 405 (89.8%) < .0001
Discharge (n = 5586) 3230 (98.4%) 2101 (91.2%) < .0001 1061 (89.6%) 635 (95.1%) 405 (89.8%) .0001
Clopidogrel
Initial (n = 5591) 2983 (90.8%) 1876 (81.4%) < .0001 959 (80.9%) 545 (81.5%) 372 (82.5%) .7499
Discharge (n = 5578) 2852 (87.0%) 1678 (73.0%) < .0001 946 (80.1%) 457 (68.4%) 275 (61.1%) < .0001
Prasugrel
Initial (n = 5591) 220 (6.7%) 36 (1.6%) < .0001 12 (1.0%) 15 (2.2%) 9 (2.0%) .0862
Discharge (n = 5587) 207 (6.3%) 29 (1.3%) < .0001 12 (1.0%) 9 (1.3%) 8 (1.8%) .4532
GP IIb/IIIa inhibitor (n = 5591) 455 (13.9%) 62 (2.7%) < .0001 18 (1.5%) 28 (4.2%) 16 (3.5%) .0013
Anticoagulants-parenteral (n = 5591) 2627 (80.0%) 1651 (71.6%) < .0001 842 (71.0%) 495 (74.0%) 314 (69.6%) .2275
Anticoagulants-oral (n = 5591) 111 (3.4%) 166 (7.2%) < .0001 98 (8.3%) 41 (6.1%) 27 (6.0%) .1255
Diagnostic/therapeutic procedures
Echocardiography (n = 5528) 2497 (76.8%) 1711 (75.1%) .1395 885 (75.8%) 509 (76.5%) 317 (71.1%) .0846
LVEF < 40% (n = 5074) 231 (7.8%) 222 (10.5%) .0007 135 (12.5%) 66 (10.4%) 21 (5.2%) .0002
Stress test (n = 5567) 28 (0.9%) 39 (1.7%) .0046 19 (1.6%) 14 (2.1%) 6 (1.3%) .602
CAG (n = 5591) 3285 (100.0%) 1120 (48.6%) < .0001 0 669 (100.0%) 451 (100.0%) < .0001
Multivessel disease (n = 4239) 1746 (55.9%) 441 (39.6%) < .0001 0 441 (66.6%) 0 < .0001
PCI (n = 5591) 3084 (93.9%)
CABG (n = 5591) 209 (6.4%)
Other discharge medications
Beta-blockers (n = 5567) 2848 (87.0%) 1896 (82.7%) < .0001 992 (84.1%) 569 (85.1%) 335 (75.3%) < .0001
ACE inhibitors/ARBs (n = 5567) 2427 (74.1%) 1719 (75.0%) .4804 901 (76.4%) 517 (77.5%) 301 (67.5%) .0002
Statins (n = 5561) 3083 (94.3%) 2012 (87.8%) < .0001 1029 (87.4%) 617 (92.4%) 366 (82.2%) < .0001
Diuretics (n = 5559) 651 (19.9%) 630 (27.5%) < .0001 381 (32.3%) 173 (25.9%) 76 (17.0%) < .0001
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAG, coronary angiography; CR,
coronary revascularization; GP, glycoprotein; LVEF, left ventricular ejection fraction; MM, medical management; PCI, percutaneous coronary intervention.
Table 3
In-hospital and 2-year Outcomes in Non—ST-segment Elevation Acute Coronary Syndrome Patients by Management Strategy
CR
n = 3285 (58.8%)
MM
n = 2306 (41.2%)
P (CR vs MM) MM P
CAG- n = 1186
(21.2%)
CAG+ CAD+ n = 669
(12.0%)
CAG+ CAD-
n = 451 (8.1%)
Hospital outcomes
Myocardial infarction 75 (2.3%) 41 (1.8%) .1943 24 (2.0%) 11 (1.7%) 6 (1.3%) .61
Recurrent ischemia 127 (3.9%) 114 (5.0%) .0494 70 (6.0%) 29 (4.4%) 15 (3.3%) .0674
Heart failure 100 (3.0%) 188 (8.2%) < .0001 139 (11.8%) 41 (6.1%) 8 (1.8%) < .0001
Ventricular arrhythmia 63 (1.9%) 28 (1.2%) .0406 13 (1.1%) 7 (1.0%) 8 (1.8%) .4788
Atrial ﬁbrillation/ﬂutter 156 (4.8%) 156 (6.8%) .0011 102 (8.6%) 33 (4.9%) 21 (4.7%) .0014
Stroke 11 (0.3%) 4 (0.2%) .2509 2 (0.2%) 2 (0.3%) 0 (0.0%) .497
Bleeding 117 (3.6%) 37 (1.6%) < .0001 13 (1.1%) 18 (2.7%) 6 (1.3%) .0281
Clinically signiﬁcant bleeding 86 (2.6%) 27 (1.2%) .9491 8 (0.7%) 14 (2.1%) 5 (1.1%) .4968
2-year outcomes
Mortality 135 (4.4%) 233 (11.0%) < .0001 158 (14.6%) 58 (9.3%) 17 (4.1%) < .0001
CV mortality 59 (1.9%) 119 (5.7%) < .0001 83 (7.9%) 31 (5.0%) 5 (1.2%) < .0001
Myocardial infarction 72 (2.4%) 80 (4.1%) .0009 47 (4.8%) 26 (4.4%) 7 (1.8%) .0421
Heart failure 29 (1.0%) 37 (1.9%) .0073 22 (2.2%) 12 (2.1%) 3 (0.8%) .202
Ventricular arrhythmia 7 (0.2%) 10 (0.5%) .1293 2 (0.2%) 7 (1.1%) 1 (0.2%) .043
Atrial ﬁbrillation/ﬂutter 10 (0.3%) 15 (0.7%) .0464 6 (0.6%) 4 (0.7%) 5 (1.2%) .4444
Stroke 20 (0.7%) 17 (0.9%) .4385 10 (1.0%) 4 (0.7%) 3 (0.8%) .7663
Bleeding 141 (4.6%) 68 (3.4%) .025 35 (3.5%) 24 (3.9%) 9 (2.2%) .2926
Clinically relevant bleed 63 (2.0%) 37 (1.8%) .5399 21 (2.1%) 14 (2.3%) 2 (0.5%) .1113
CAD, coronary artery disease; CAG, coronary angiography; CR, coronary revascularization; CV, cardiovascular; MM, medical management.
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DISCUSSION
The results of this large international cohort study can help us
to understand the heterogeneity of patients with NSTEACS, the
main clinical pathways leading to MM, and its inﬂuence on
prognosis. Our observations also allow us to estimate post-
discharge event rates in relation to these pathways in a large
cohort of unselected patients surviving NSTEACS. This information
can be particularly helpful for risk stratiﬁcation, clinical follow-up
planning, and designing future studies in this ﬁeld.
Patients surviving acute coronary syndrome are at high risk of
subsequent cardiovascular events, even if optimally treated.19
Despite recommendations by the main European guidelines,1,2 less
than 60% of patients undergo CR during hospitalization for
NSTEACS. This is clinically relevant given the abundance of data
from randomized trials13,20,21 and observational studies,22 suggest-
ing an improvement in mid- and long-term prognosis for patients
with NSTEACS managed invasively. In our study, the most frequent
clinical situation associated with MM is lack of CAG during
hospitalization, which accounts for roughly half of MM cases. Our
study is consistent with previous studies using similar analytical
methods insofar as older and sicker patients are more often selected
for MM while younger and lower risk patients consistently receive
more aggressive treatment. This is also true among subgroups of
MM patients, as those not undergoing CAG show the highest risk
proﬁle. Similar ﬁndings were reported in an analysis of the FAST-MI
registry, in which MM patients with non—ST-segment elevation
myocardial infarction who did not undergo CAG had a higher 5-year
mortality rate than those who did, even compared with CAG+
patients with multivessel disease.23 Moreover, our ﬁndings are
consistent with the risk paradox found in several national and
international registries,23–27 with a gradient in age, cardiovascular
burden, and comorbidities between revascularized patients,
patients undergoing CAG but not CR and, ﬁnally, those not receiving
CAG. Although selection bias may partially explain the higher risk
observed in MM patients, CR remains independently associated
with lower 2-year mortality risk in our population after adjustment
for all factors associated with postdischarge mortality in a
previously developed predictive model.18
While CAG per se is unlikely to provide any beneﬁt, it has been
suggested that patient selection (ie, whether or not to perform
angiography) plays a crucial role.28 In the EPICOR study, NSTEACS
patients who did not undergo CAG were more likely to be older, with
unstable angina rather than non—ST-segment elevation myocardial
infarction, and to have hypertension or diabetes. In the TRILOGY ACS
trial, the most frequent reasons for not undergoing CAG were patient
refusal, lack of on-site facilities, and either unsuitable coronary
anatomy or other contraindications.10 Noncatheterized patients
were also more likely to be older, female, and to have a diagnosis of
unstable angina rather than non—ST-segment elevation myocardial
infarction, and less previous coronary intervention. In a retrospective
analysis of the TRILOGY ACS trial, NSTEACS patients who did not
undergo angiography also had signiﬁcantly poorer outcomes
compared with those who did: at 30 months, cardiovascular death
rates were 8.2% and 4.7%, respectively, with all-cause death rates of
9.6% and 5.8%.7 In EPICOR, as in other studies,29 lack of immediate
access to coronary intervention facilities was one of the most
important reasons for initial conservative management. This is true
even though transfers between hospitals and the reasons for transfer
were recorded in EPICOR.30
The regional differences in the probability of undergoing CAG
and CR as well as the increased probability of undergoing
revascularization are worthy of mention. These are probably
largely explained by differences in resources, insurance level and
care access opportunities, procedural cost for patients, and
reimbursement.
Table 4
Hazard Ratios for 2-year All-cause Death in Subgroups of Medically Managed
vs Revascularized NSTEACS Patients by Management Strategy. Model Adjusted
for Hospital Type (Regional, non-University General, University General,
Private) and Geographical Region, Using a Multilevel Model to Adjust for
Clustering
Adjusted for Group HR for death vs revascularized
No adjustment CAG– 3.30 (2.54 to 4.27)
CAG+ CAD+ 2.12 (1.54 to 2.92)
CAG+ CAD– 0.86 (0.50 to 1.47)
Age and sex CAG– 2.52 (1.94 to 3.27)
CAG+ CAD+ 1.88 (1.36 to 2.58)
CAG+ CAD– 0.96 (0.56 to 1.64)
EPICOR risk score covariates CAG– 1.81 (1.23 to 2.65)
CAG+ CAD+ 1.90 (1.23 to 2.95)
CAG+ CAD– 0.68 (0.21 to 2.21)
CAD, coronary artery disease; CAG, coronary angiography; HR, hazard ratio;
NSTEACS, non—ST-segment elevated acute coronary syndrome.
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Figure 2. Postdischarge event rates at 2 years according to management
strategy. A: All-cause mortality. B: Cardiovascular events. C: Bleeding events.
Cardiovascular events included myocardial infarction, heart failure,
arrhythmia, unstable angina, ischemic stroke, and transient ischemic attack.
Bleeding events included all kinds of bleeds. CAD, coronary artery disease;
CAG, coronary angiography; CR, coronary revascularization; MM, medical
management.
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Limitations
This study is based on registry data and is therefore subject to
the limitations of observational studies, ie, potential bias and
confounding. The role of patient preferences in the decision to
undergo CAG and CR was not recorded, which may have had an
additional inﬂuence on the outcomes that could not be measured.
The analysis of hospital procedures alone excluded patients in
which scheduled CAG or CR might have been performed. However,
when we used wider time frames for CR–10 days (as in TRILOGY
ACS) and 30 days–there were no signiﬁcant changes in our results,
conﬁrming the consistency of our ﬁndings. As mentioned
previously, although our multivariable analysis included a rigorous
adjustment using a previously developed model for mortality
prediction,18 unmeasured confounders, such as known CAD not
amenable for CR, dementia, too sick for other medical reasons, or
patient preferences, could have affected the apparent protective
role of CAG and CR. In addition, clinical events during follow-up
were not centrally adjudicated. Finally, although we attempted to
show representative examples of real-life practice in each country,
by careful selection of local centers, caution is warranted in
generalizing the results.
CONCLUSIONS
Medically managed patients with NSTEACS constitute a
heterogeneous group according to the clinical pathways leading
to nonuse of CAG or CR. Compared with CR patients, those who do
not undergo CAG during hospitalization are older and present with
greater comorbidity. They also have the highest adjusted mortality
risk after discharge, followed by those not revascularized despite
signiﬁcant CAD. Therefore, the clinical pathways leading to MM are
clinically relevant and should be taken into consideration in
studies addressing this patient group, given the observed
differences in baseline characteristics and clinical outcomes.
Continuing efforts are needed to improve adherence to guideline
recommendations, particularly for NSTEACS patients admitted to
hospitals without a catheterization laboratory.
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WHAT IS KNOWN ABOUT THE TOPIC?
– Despite guideline recommendations for an invasive
strategy in most patients with NSTEACS, a large
proportion of these patients are initially selected for MM.
– Different clinical pathways lead to the selection of MM
in NSTEACS patients.
– NSTEACS patients who do not undergo CAG, and hence
do not undergo CR, are at highest risk of cardiovascular
morbidity and mortality in the long-term.
WHAT DOES THE STUDY ADD?
– MM is independently associated with a higher 2-year
adjusted mortality risk compared with revascularization.
– The different clinical pathways leading to the selection
of MM in NSTEACS patients have an important inﬂuence
on patient outcomes.
– Therefore, the reasons for MM should be taken into
consideration in future studies addressing this patient
population.
SUPPLEMENTARY MATERIAL
Supplementary material associated with this article can
be found in the online version available at doi:10.1016/j.
rec.2016.12.031.
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